Take normalized and institutionalized measures to reduce the medical burden of the masses-
centralized procurement will gradually cover all kinds of drugs
Beijing, January 29 (Reporter Wu Jiajia) Recently, the executive meeting of the State Council has deployed to further promote the reform of centralized drug procurement, adopt normalized and institutionalized measures to reduce the burden of medical treatment of the masses, and issued relevant opinions.
On the 29th, the State Council Information Office held a regular policy briefing to introduce the relevant situation. Chen Jinfu, deputy director of the National Medical Security Administration, said that it will promote the normalization and institutionalization of centralized drug procurement.
Centralized procurement will gradually cover all kinds of drugs, focusing on including drugs with large amounts and high purchase amounts in the basic medical insurance drug catalog, guiding drug prices to return to a reasonable level, and reducing the burden of drug use by the people.
Chen Jinfu said that for a long time, the problems of falsely high prices and irregular circulation in the medical field in my country have increased the burden of medication for patients.
In November 2018, the Central Comprehensive Deepening Reform Committee meeting reviewed and approved the "National Organization of Drug Centralized Procurement Pilot Program". In accordance with the central decision and deployment, the Medical Insurance Bureau, in conjunction with the Health Commission, the Food and Drug Administration and other relevant departments, organized and carried out the pilot work. Eleven cities such as Beijing and Shanghai have begun to expand to the whole country. So far, the second and third batches of centralized drug procurement have been carried out.
At present, the fourth batch of centralized procurement has begun, and it is expected that the masses will be able to enjoy the fourth batch of centralized procurement in May this year.
In the past two years, breakthrough results have been achieved in the reform of centralized drug procurement.
The first three batches of nationally organized drug procurement involved a total of 112 varieties, and the average drop of selected products reached 54%. As of 2020, the actual procurement volume has reached 2.4 times the agreed procurement volume, and the overall cost savings exceeded 100 billion yuan. It reduces the burden on patients, and at the same time eradicates the phenomenon of "dead by price cut" in the past, eliminates the phenomenon of random withdrawal of recruitment platforms, and improves the availability of medicines for the masses.
At the same time, local governments have carried out centralized procurement of drugs in accordance with the basic rules of the state to organize centralized procurement. The provincial centralized procurement has reached 259 varieties, which can save 24 billion yuan each year.
In order to ensure that the drugs selected in the centralized procurement reach the medical institutions, the relevant departments first unblock the policy channels for prioritization and use, and require all public medical institutions to participate in centralized procurement.
Wang Xuetao, head of the Department of Pharmaceutical Affairs of the National Health Commission, said that relevant opinions put forward reform measures from two aspects: dynamic adjustment of medical service prices and strengthening of management assessment.
For example, a medical institution sets a procedure for preferentially recommending and selecting selected drugs in the doctor's prescription system, and requires pharmacists to strengthen prescription review and deployment.
In terms of the performance appraisal and distribution of public hospitals, the target responsibility appraisal of the heads of medical institutions, etc., it is required to include the procurement and use of drugs selected from the national centralized procurement into the assessment content.
In the next step, relevant departments will focus on four aspects of work.
The first is to normalize the centralized procurement of drugs organized by the state.
The second is to guide local governments to standardize centralized drug procurement.
The third is to promote the standardization and standardization of the centralized drug procurement platform.
The fourth is to implement relevant policies.
Strengthen the quality supervision of the selected products, urge the selected companies to do a good job in the production and supply of the selected products, supervise and monitor the clinical use of medical institutions, further improve the incentive mechanism, and mobilize the enthusiasm of all parties to participate in the reform, including the enthusiasm of medical institutions and medical staff, to ensure the quality of the selected products , Supply, use.
Wu Jiajia